Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) Director John T. Cardis sold 6,000 shares of Edwards Lifesciences Corp stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $97.92, for a total value of $587,520.00. Following the sale, the director now directly owns 46,708 shares of the company’s stock, valued at approximately $4,573,647. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

EW has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday, July 31st. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $90.06.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 0.08% during mid-day trading on Tuesday, hitting $97.97. The stock had a trading volume of 580,853 shares. Edwards Lifesciences Corp has a 1-year low of $60.62 and a 1-year high of $98.27. The stock has a 50-day moving average of $89.95 and a 200-day moving average of $80.21. The company has a market cap of $10.388 billion and a price-to-earnings ratio of 14.13. Edwards Lifesciences Corp also was the target of a large decrease in short interest in July. As of July 31st, there was short interest totalling 2,915,578 shares, a decrease of 45.6% from the July 15th total of 5,356,970 shares. Approximately 2.8% of the company’s shares are sold short. Based on an average daily trading volume, of 1,687,462 shares, the short-interest ratio is currently 1.7 days.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.29 earnings per share for the current fiscal year.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.